Zusammenfassung
Neuroendokrine Lungentumoren treten insgesamt selten auf. Diese Gruppe umfasst vier Tumorarten: die typischen (TC) und atypischen (AC) Karzinoidtumoren, die großzelligen neuroendokrinen Karzinome (LCNC) sowie die kleinzelligen Karzinome (SCNC). Die Tumoren unterscheiden sich histologisch in ihrer Mitoserate und dem Auftreten von Nekrosen. Es empfiehlt sich, nach Abschluss der Staginguntersuchungen die Befunde in einem interdisziplinären Tumorboard zu besprechen und eine Therapieempfehlung zu erarbeiten. Bei den TC und AC steht die Operation im Vordergrund. Wenn möglich, wird eine anatomische Resektion mit einer radikalen mediastinalen Lymphadenektomie durchgeführt. Bei den LCNC und SCNC liegt meist schon ein fortgeschrittenes Stadium vor, sodass sich nur in ausgewählten Fällen eine Operation empfiehlt. In den überwiegenden Fällen wird eine Chemotherapie ggf. in Kombination mit einer Bestrahlung durchgeführt. Die Langzeitprognose hängt von der Tumoraggressivität ab und ist bei den typischen Karzinoidtumoren am besten und bei den kleinzelligen Karzinomen am schlechtesten.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Amar D, Zhang H, Roistacher N (2002) The incidence and outcome of ventricular arrhythmias after noncardiac thoracic surgery. Anesth Analg 95(3):537–543
Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y, … Nagai K (2006) Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol 24(1):70–76
Blanc K, Dechartres A, Zaimi R, Lefebvre A, Janet-Vendroux A, Fournel L, … Rabbat A (2018) Patients experiencing early acute respiratory failure have high postoperative mortality after pneumonectomy. J Thorac Cardiovasc Surg 156(6):2368–2376
Bromińska B, Czepczyński R, Gabryel P, Jarmołowska-Jurczyszyn D, Janicka-Jedyńska M, Sawicka-Gutaj N, … Ruchała M (2019) 18F-FDG PET/CT and nestin expression as prognostic tools in pulmonary neuroendocrine tumours. Nucl Med Commun 40(4):353–360
Cantarutti A, Galeone C, Leuzzi G, Bertocchi E, Pomponi G, Langer M, … Pastorino U (2018) Thirty-day mortality and five-year survival in thoracic surgery: „real-world“ assessment of outcomes from a single-institution audit. Tumori 104(2):96–104
Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, … Travis WD (2015) Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol 26(8):1604–1620
Chassagnon G, Bennani S, Revel MP (2017) New TNM classification of non-small cell lung cancer. Rev Pneumol Clin 73(1):34–39
Chong S, Lee KS, Kim BT, Choi JY, Yi CA, Chung MJ, … Lee JY (2007) Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications. AJR Am J Roentgenol 188(5):1223–1231
Crona J, Fanola I, Lindholm DP, Antonodimitrakis P, Öberg K, Eriksson B, Granberg D (2013) Effect of temozolomide in patients with metastatic bronchial carcinoids. Neuroendocrinology 98(2):151–155
Daniels CE, Lowe VJ, Aubry MC, Allen MS, Jett JR (2007) The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. Chest 131(1):255–260
Dotzenrath C, Goretzki PE, Cupisti K, Yang Q, Simon D, Röher HD (2001) Malignant endocrine tumors in patients with MEN 1 disease. Surgery 129(1):91–95
Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, … Skogseid B (2007) Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 13(10):2986–2991
Faiss S, Pape UF, Böhmig M, Dörffel Y, Mansmann U, Golder W, … Wiedenmann B (2003) Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors – the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21(14):2689–2696
Ferolla P, Daddi N, Puma F, Crinò L (2014) Postsurgical follow-up is always necessary in bronchial carcinoid. Ann Thorac Surg 98(3):1143–1144
Filosso PL, Falcoz PE, Solidoro P, Pellicano D, Passani S, Guerrera F, Ruffini E (2018) The European Society of Thoracic Surgeons (ESTS) lung neuroendocrine tumors (NETs) database. J Thorac Dis 10(Suppl 29):S3528–S3532
Fine RL, Gulati AP, Krantz BA, Moss RA, Schreibman S, Tsushima DA et al (2013) Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience. Cancer Chemother Pharmacol 71(3):663–670
Granberg D, Sundin A, Janson ET, Oberg K, Skogseid B, Westlin JE (2003) Octreoscan in patients with bronchial carcinoid tumours. Clin Endocrinol 59(6):793–799
Guarino C, Mazzarella G, De Rosa N, Cesaro C, La Cerra G, Grella E, … Bianco A (2016) Pre-surgical bronchoscopic treatment for typical endobronchial carcinoids. Int J Surg 33(Suppl 1):S30–S35
Hendifar AE, Marchevsky AM, Tuli R (2017) Neuroendocrine tumors of the lung: current challenges and advances in the diagnosis and management of well-differentiated disease. J Thorac Oncol 12(3):425–436
Huang J, Li S, Hao Z, Chen H, He J, Xu X, … He J (2016) Complete video-assisted thoracoscopic surgery (VATS) bronchial sleeve lobectomy. J Thorac Dis 8(3):553–574
Jackson AS, Rosenthal A, Cattoni M, Bograd AJ, Farivar AS, Aye RW, … Louie BE (2020) Staging system for neuroendocrine tumors of the lung needs to incorporate histologic grade. Ann Thorac Surg 109(4):1009–1018
Kaifi JT, Kayser G, Ruf J, Passlick B (2015) The diagnosis and treatment of bronchopulmonary carcinoid. Dtsch Arztebl Int 112(27–28):479–485
Kayani I, Conry BG, Groves AM, Win T, Dickson J, Caplin M, Bomanji JB (2009) A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J Nucl Med 50(12):1927–1932
Knorring J von, Lepäntalo M, Lindgren L, Lindfors O (1992) Cardiac arrhythmias and myocardial ischemia after thoracotomy for lung cancer. Ann Thorac Surg 53(4):642–647
Leboulleux S, Dromain C, Vataire AL, Malka D, Aupérin A, Lumbroso J, … Baudin E (2008) Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 93(8):3021–3028
Lee HK, Lee HS, Kim KI, Shin HS, Lee JW, Kim HS, Cho SW (2011) Outcomes of sleeve lobectomy versus pneumonectomy for lung cancer. Korean J Thorac Cardiovasc Surg 44(6):413–417
Lim E, Goldstraw P, Nicholson AG, Travis WD, Jett JR, Ferolla P, … Crowley J (2008) Proceedings of the IASLC international workshop on advances in pulmonary neuroendocrine tumors 2007. J Thorac Oncol 3(10):1194–1201
Lococo F, Cesario A, Paci M, Filice A, Versari A, Rapicetta C, … Treglia G (2014) PET/CT assessment of neuroendocrine tumors of the lung with special emphasis on bronchial carcinoids. Tumour Biol 35(9):8369–8377
Mariniello A, Bodei L, Tinelli C, Baio SM, Gilardi L, Colandrea M, … Grana CM (2016) Long-term results of PRRT in advanced bronchopulmonary carcinoid. Eur J Nucl Med Mol Imaging 43(3):441–452
Okereke I, Murthy SC, Alster JM, Blackstone EH, Rice TW (2005) Characterization and importance of air leak after lobectomy. Ann Thorac Surg 79(4):1167–1173
Oronsky B, Ma PC, Morgensztern D, Carter CA (2017) Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia 19(12):991–1002
Park CM, Goo JM, Lee HJ, Kim MA, Lee CH, Kang MJ (2009) Tumors in the tracheobronchial tree: CT and FDG PET features. Radiographics 29(1):55–71
Predina JD, Kunkala M, Aliperti LA, Singhal AK, Singhal S (2010) Sleeve lobectomy: current indications and future directions. Ann Thorac Cardiovasc Surg 16(5):310–318
Radu DM, Jauréguy F, Seguin A, Foulon C, Destable MD, Azorin J, Martinod E (2007) Postoperative pneumonia after major pulmonary resections: an unsolved problem in thoracic surgery. Ann Thorac Surg 84(5):1669–1673
Rekhtman N (2010) Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med 134(11):1628–1638
Sirbu H, Busch T, Aleksic I, Lotfi S, Ruschewski W, Dalichau H (1999) Chest re-exploration for complications after lung surgery. Thorac Cardiovasc Surg 47(2):73–76
Sullivan I, Le Teuff G, Guigay J, Caramella C, Berdelou A, Leboulleux S, … Planchard D (2017) Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids. Eur J Cancer 75:259–267
Tsuruoka K, Horinouchi H, Goto Y, Kanda S, Fujiwara Y, Nokihara H, … Ohe Y (2017) PD-L1 expression in neuroendocrine tumors of the lung. Lung Cancer 108:115–120
Wirth LJ, Carter MR, Jänne PA, Johnson BE (2004) Outcome of patients with pulmonary carcinoid tumors receiving chemotherapy or chemoradiotherapy. Lung Cancer 44(2):213–220
Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E et al (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387(10022):968–977
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2023 Der/die Autor(en), exklusiv lizenziert an Springer-Verlag GmbH, DE, ein Teil von Springer Nature
About this chapter
Cite this chapter
Kirschbaum, A. (2023). Neuroendokrine Neoplasien der Bronchien. In: Bartsch, D.K., Holzer, K. (eds) Endokrine Chirurgie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-63317-5_49
Download citation
DOI: https://doi.org/10.1007/978-3-662-63317-5_49
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-63316-8
Online ISBN: 978-3-662-63317-5
eBook Packages: Medicine (German Language)